C. Bengala

发表

Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

P. Conte, G. Luppi, F. Bertolini, 2007, International journal of radiation oncology, biology, physics.

Dose and outcome: the hurdle of neutropenia (Review).

Pier Franco Conte, M. Marangolo, P. Conte, 2006, Oncology reports.

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

C. Boni, C. Giovane, P. Conte, 2009, British Journal of Cancer.

Current State of the Treatment in Metastatic Breast Cancer

P. Conte, C. Bengala, 2006 .

High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.

L. Mariani, C. Carlo-Stella, M. Di Nicola, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

A. Ballestrero, P. Pedrazzoli, P. Conte, 2006, British Journal of Cancer.

Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.

C. Orlandini, P. Conte, C. Bengala, 2001, Oncology.

Oropharyngeal squamous cell carcinoma and HPV. Systematic review on overall management.

M. Spinosi, J. Cambi, C. Bengala, 2017, Journal of stomatology, oral and maxillofacial surgery.

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

P. Conte, G. Luppi, T. Scolaro, 2009, International journal of radiation oncology, biology, physics.

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

S. Bettelli, A. Maiorana, P. Conte, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

E. Giovannetti, U. Boggi, S. Ricci, 2005, British Journal of Cancer.

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients

C. Tibaldi, P. Conte, E. Montanaro, 2004, Breast Cancer Research and Treatment.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte‐colony stimulating factor administered to patients with metastatic breast carcinoma

C. Tibaldi, R. Vanacore, A. Mazzoni, 1998, Cancer.

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.

C. Orlandini, P. Bruzzi, R. Danesi, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

A. Brandes, L. Gianni, P. Morandi, 2018, European journal of cancer.

Controversies of chemotherapy for the treatment of metastatic breast cancer

P. Conte, C. Bengala, V. Guarneri, 2007 .

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support

C. Orlandini, P. Conte, C. Bengala, 2004, Bone Marrow Transplantation.

Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.

P. Conte, C. Bengala, A. Romanini, 1996, American journal of clinical oncology.

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.

P. Pedrazzoli, D. Blaise, D. Niederwieser, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

J. Ledermann, C. Orlandini, P. Conte, 2005, Bone Marrow Transplantation.

Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.

R. Barakat, D. Spriggs, M. Moore, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells.

M. Boccadoro, A. Pileri, G. Bonadonna, 1990, Bone marrow transplantation.

A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose Chemotherapy (SDC) for first-line treatment of ovarian cancer

J. Ledermann, A. Hinke, H. Wandt, 2005 .

Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2017 .

Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)

P. Conte, C. Bengala, V. Guarneri, 2007, Breast Cancer Research.

Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34(+) cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support.

R. Consolini, P. Conte, C. Bengala, 2001, Haematologica.

High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).

C. Orlandini, F. Innocenti, R. Danesi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.

A. Ballestrero, P. Pedrazzoli, G. Martinelli, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.

A. Howell, R. Coombes, A. Tres, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Two‐point‐NGS analysis of cancer genes in cell‐free DNA of metastatic cancer patients

D. Galimberti, A. Pinto, F. Fava, 2020, Cancer medicine.

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

N. Ibrahim, J. Sparano, R. Finn, 2009 .

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

A. Ballestrero, P. Pedrazzoli, P. Conte, 2006, British Journal of Cancer.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

C. Orlandini, R. Danesi, S. Fogli, 2001, Breast Cancer Research and Treatment.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program

E. Vasile, F. Cappuzzo, L. Crinò, 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients

E. Vasile, G. Fasola, D. Galetta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

N. Ibrahim, J. Sparano, R. Finn, 2011, Clinical Cancer Research.

Recent advances in managing triple-negative breast cancers

C. Bengala, 2009, F1000 medicine reports.

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

S. Bettelli, P. Conte, G. Luppi, 2010, British Journal of Cancer.

Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

P. Conte, C. Bengala, V. Guarneri, 2007, Clinical breast cancer.

High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.

P. Pedrazzoli, D. Blaise, F. Lanza, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry

A. Ballestrero, P. Pedrazzoli, M. Aglietta, 2013, Bone Marrow Transplantation.

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

C. Higano, A. Bryce, J. García-Foncillas, 2021, JAMA network open.

Paclitaxel plus epirubicin in advanced breast cancer.

P. Conte, C. Bengala, A. Gennari, 1998, Oncology.

Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.

G. Bonadonna, P. Valagussa, R. Giardini, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study

F. Innocenti, O. Biadi, R. Danesi, 2003, Bone Marrow Transplantation.

1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients

E. Vasile, G. Ceresoli, R. Chiari, 2017 .